Volume 74, Issue 2 , Pages 404-411, 1 June 2009
Recognizing False Biochemical Failure Calls After Radiation With or Without Neo-Adjuvant Androgen Deprivation for Prostate Cancer
To access this article, please choose from the options below
Supported by the Australian Government National Health and Medical Research Council (Project Grant Applications 9936572, 209801, 455520); Hunter Medical Research Institute (Newcastle, Australia); AstraZeneca Pty Ltd (Sydney, Australia); and Schering-Plough Pty Ltd (Sydney, Australia).
Conflict of interest: David Lamb—support to attend meetings from AstraZeneca. David Joseph—honoraria associated with membership of AstraZeneca's Breast Cancer Medical Advisory Board. John Matthews—support to attend Australasian meetings by AstraZeneca and Schering Plough. Keen-Hun Tai—received a FROGG-AstraZeneca educational grant in 2003 and was supported by AstraZeneca to attend two Casodex Investigators Meetings in 2001 and 2004. Nigel Spry—honararia associated with AstraZeneca and Schering Plough; research funding from Schering Plough. David Christie—partial sponsorship to attend ASCO 2007 by AstraZeneca. Allison Steigler—support from AstraZeneca to attend one meeting. James Denham, Mahesh Kumar, Paul Gleeson, Chris Atkinson, Sandra Turner, Peter Greer, and Catherine D'Este have no disclosures to make.
PII: S0360-3016(08)03515-3
doi:10.1016/j.ijrobp.2008.08.047
© 2009 Elsevier Inc. All rights reserved.
Volume 74, Issue 2 , Pages 404-411, 1 June 2009
